Prospective, Multi-Center, Observational Program to Assess Routine Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in the Russian Federation
Phase of Trial: Phase IV
Latest Information Update: 13 Jul 2015
At a glance
- Drugs Leuprorelin (Primary) ; Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 10 Jun 2017 Biomarkers information updated
- 08 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jan 2014 to 1 Mar 2014.